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Abstract: Protein tyrosine kinases (PTKs) are the most potential therapeutic targets for cancer. 
Herein, we present a sound rationale for synthesis of a series of novel 2-(methylthio), 2-(substituted 
alkylamino), 2-(heterocyclic substituted), 2-amino, 2,4-dioxo and 2-deoxo-5-deazaalloxazine 
derivatives by applying structure-based drug design (SBDD) using AutoDock 4.2. Their antitumor 
activities against human CCRF-HSB-2, KB, MCF-7 and HeLa have been investigated in vitro. Many 
5-deazaalloxazine analogs revealed high selective activities against MCF-7 tumor cell lines (IC50: 
0.17–2.17 µM) over HeLa tumor cell lines (IC50 > 100 µM). Protein kinase profiling revealed that 
compound 3h induced multi- targets kinase inhibition including −43% against (FAK), −40% against 
(CDKI) and −36% against (SCR). Moreover, the Annexin-V/PI apoptotic assay elucidate that 
compound 3h showed 33% and potentially 140% increase in early and late apoptosis to MCF-7 cells 
respectively, compared to the control. The structure-activity relationship (SAR) and molecular 
docking study using PTK as a target enzyme for the synthesized 7-deazaalloaxazine derivatives 
were investigated as potential antitumor agents. The AutoDock binding affinities of the 5-
deazaalloxazine analogs into c-kit PTK (PDB code: 1t46) revealed reasonable correlations between 
their AutoDock binding free energy and IC50. 
Keywords: deazaalloxazine; antitumor; AutoDock; selectivity; protein kinase 
 
1. Introduction 
Cancer is a severe health problem in the United States. In 2020, there have been more than 1.8 
million new cases diagnosed with cancer and nearly 606,520 died from it in the US [1]. The implication 
of protein tyrosine kinases (PTKs in various forms of cancers made them significant targets in drug 
discovery. The selective PTK inhibitors are prospective candidates as antitumor agents by inhibiting 
multiple pathways in cancer cells, such as proliferation, survival and angiogenesis [2]. Consequently, 
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the synthesis of small molecules as PTK inhibitors (PTKIs) has developed into a remarkable approach 
toward new therapeutics [3]. After the Food and Drug Administration (FDA) approval for imatinib 
in 2001, they become a trend as potential anticancer drugs to the market [4]. Nowadays, there are 
more than twenty FDA-approved PTKIs for cancer therapy [5]. 
Interestingly, the in vivo antitumor activity of 2-deoxo-10-methyl-2-phenyl- 5-deazaflavin (I) 
against subcutaneously transplanted human adenocarcinoma A431 xenograft into BALB/c nude mice 
was reported early by our research group [6]. In this study, the tumor volume was reduced to 53.4% 
of the intraperitoneal administration after 10 days (100 mg/kg; i.p.) as shown in Figure 1. 
Furthermore, we investigated the antitumor activities of 5-deazaflavins and flavins derivatives 
against a variety of cancer cell lines and elucidated that these candidates could be promising 
antitumor drugs [7,8]. 
 
Figure 1. One hundred mg/kg, i.p., of compound I reduced the tumor volume of Subcutaneous (SC) 
implanted A431 into nude mouse 53.4% after 10 days of 100 mg/kg, ip. 
The potential antitumor activity of 5-deazaalloxazines {pyrimido[4,5-b] quinoline-2,4(1H, 3H)-
diones} is attributed to their structural similarities with the scaffold of 5-deazaflavins {pyrimido[4,5-
b] quinoline-2,4(3H, 10H)-diones} [9]. The condensed pyrimido[4,5-b] quinoxaline cyclic systems are 
called "alloxazines” which exist in two tautomeric forms, one of which, when "frozen" by substitution 
of the hydrogen atom at N (10), is the source of the isoalloxazine series [10] as shown in Figure 2. 
 
Figure 2. Structures of flavin, 5-deazaflavin, alloxazine, 5-deazaalloxazins and the well-known kinase 
inhibitors (imatinib and lapatinib). 
Computer-aided drug design (CADD) is a powerful model for drug discovery, where several 
computationally designed drugs are currently under clinical investigations and even marketed, such 
as Dorzolamide, Saquinavir, Aliskiren [11,12]. Recent applications of computational chemistry 
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comprising both Structure-Based Drug Design (SBDD) and Ligand-Based Drug Design (LBDD) 
approaches in the discovery and design of kinase inhibitors were intensively implemented in the 
design and discovery of many kinase inhibitors such as imatinib (Figure 2) [13,14]. Multi-targeted 
therapy is a powerful category for eradication of cancer cells; therefore, CADD tools are fundamental 
in the discovery and development of anticancer drugs [15–17]. SBDD techniques such as homology 
modeling, molecular dynamics (MD) simulations and docking have been applied for lead 
optimization based on the binding sites of therapeutic target proteins [18–20]. Molecular docking is 
the most advanced technique for lead optimization by investigation of the binding affinities of 
compounds into the binding cavities of the therapeutic target protein. AutoDock is the most 
commonly cited software docking program in the scientific literature Figure 3 [21]. The docking 
binding affinity studies for many 5-deazaflavin derivatives into PTK have been reported [10,22–24]. 
 
Figure 3. The rate of citation of different molecular docking programs, in which Autodock, GOLD 
and Glide are the most commonly used ones, modified through reference [21]. 
For the aforementioned facts, new derivatives of flavin and deazaflavin derivatives compounds 
are still in demand to enhance their binding affinity into the targeted kinases and consequently their 
and the antitumor activities. Moreover, our earlier results [7] have identified several key features 
through Structure Activity Relationship (SAR) study of the different flavin analogs to impact the 
maximum binding affinity by the following structural characteristics: (1) no substituent at the N-10 
position on 5-deazaflavins, flavins and flavin-5-oxide analogs, (2) hydrogen at the N-3 position, (3) 
Ph or NH2 group at the C-2 position. These preliminary studies prompted us to synthesize new 5-
deazaalloxazines analogs based on SBDD for structural optimization of our reported compounds to 
reveal higher selectivity against different kinases and tumor cell lines. 
2. Results and Discussion 
2.1. Synthesis and Structural Elucidation of 5-Deazaalloxazine Derivatives 
The prerequisite starting material, 6-(N-alkylanilino)-2-methylthiopyrimidin- 4(3H)-ones (1a–e) 
were prepared by alkylation of 2,3-dihydro-6-(N-arylamino)-2-thioxopyrimidin-4(1H)-ones [8] with 
alkyl iodide in 2 M NaOH at 0–5 °C for 30 min in 61–90% yields [21]. The intermediate compounds, 
2-deoxo-2-alkylthio-5- deazaalloxazines (2a–e) were prepared according to the reported method 
[10,13] by the reaction of 6-(N-alkylanilino)-2-alkylthiopyrimidin-4(3H)-ones (1a–e) with Vilsmier 
reagent (dimethylformamide-phosphorus oxycholride-DMF-POCl3) at 90 °C for 1–4 h in 72–86% 
yields. Amination of 2-alkylthiopyrimidine and 5-deazaalloxazine analogs via reaction with different 
alkyl and aryl amines has long been investigated [8,25,26]. The carbons adjacent to nitrogens of 
pyrimidine moieties of 5-deazaalloaxzine are susceptible to nucleophilic substitution reactions 
because of the  electron-deficient nature. Thus, the different amination reactions have been done by 
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substitution of 2-methylthio group with different amines for preparation of 2-(substituted 
alkylamino)-, 2-(heterocyclic substituted)- and 2-amino-2-deoxo-5-deazaalloxazines {pyrimido[4,5-b] 
quinoline-4(3H)-one derivatives} (3a–m, 4a–g and 5a,b) as represented in Scheme 1. These derivatives 
(3a–m, 4a–g and 5a,b) have higher aqueous solubility because of their polar side chain bearing 
different amino groups at position 2, which may be the predisposing factor for boosting their potency 
and selectivity. 
2-(Substituted alkyl amino)-2-deoxo-5-deazaalloxazines (3a–m) were synthesized by heating 
under reflux the compounds 2-deoxo-2-alkylthio- 5-deazaalloxazines (2) with an appropriate 
primary amine including ethanolamine, n-butylamine, n-propylamine, and/or cyclohexylamine for 
7–9 h. The products (3a–m) were obtained as yellow needles in 60–88% yields. Moreover, a variety of 
substitutions namely, 2-piperidin-1-yl, 2-morpholin-4-yl and 2-piprazin-4-yl of 2-deoxo-5-
deazaalloxazines (4a–g) were prepared by refluxing of the intermediate compounds (2) with an 
appropriate secondary amine including morpholine, piperidine, and/or N-phenylpiperazine in 
dimethylformamide (DMF) for 24–30 h. All the products of (4a–g) were afforded as needles with 
bright yellow color in 64–75% yields. Whereas, 2-amino-2-deoxo-5-deazaalloxazines (5a,b) were 
synthesized by fusion of 2-deoxo-2-alkylthio-5-deazaalloxazines (2) with ammonium acetate for 0.5–
3 h at 160–165 °C to produce the corresponding 5-deazaalloxazines (5a,b) as yellow needles in 69–
83% yields. The excess amines, in the above reactions involving treatment with volatile amines, were 
evaporated under vacuo. While, the high boiling point amines such as piperidine, morpholine and 
N-phenylpiperazine were separated from residue by treating with water or ethanol to get amine-free 
products. 
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Scheme 1. General methods for the preparation of 2-deoxo-2-alkylthio-5-deazaalloxazines (2a–e), 2-
(substituted alkyl amino)-2-deoxo-5-deazaalloxazines (3a–m), 2-(heterocyclic substituted)-2-deoxo-5-
deazaalloxazines (4a–g), 2-amino-2-deoxo-5-deazaalloxazines (5a,b), 2,4-dioxo-5-deazaalloxzines 
(6a–c), 2-deoxo-5-deazaalloxazine (8). Reagents and conditions: (a) DMF-POCl3, 90 °C, 1–4 h; (b) 
R1NH2, DMF, reflux 7–9 h; (c) 2ry amine, DMF, reflux 24–30 h; (d) CH3COONH4, 160–165 °C, 0.5–1.5 h; 
(e) 5 M HCl, reflux, 15 h; (f) Raney Ni, absolute ethanol, 0.5 h; (g) DMF-POCl3, 90 °C, 2 h. 
Acidic hydrolysis of the intermediate 2-deoxo-2-alkylthio-5-deazaalloxazines (2) in 5 M 
hydrochloric acid by heating under reflux for 10–15 h produces the corresponding 2,4-dioxo-5-
deazaalloxzines (6a–c) as sharp yellow needles in 62–84% yields. Desulfurization of the alkyl 
mercapto substituent is often a critical step in heterocyclic synthesis, particularly in pyrimidine 
chemistry [27]. The most commonly used method of desulfurization is to reflux the target compound 
with an excess of Raney nickel (Mozingo conditions) [28]. According to Mozingo, R. et al., two courses 
for the reaction of sulfide may be postulated. In the first of these, the nickel is considered to function 
as a metal removing the sulfur in the Wurtz-type reaction, Figure 4a. Alternatively, in the presence 
of sufficient Raney nickel catalyst, to contain an excess of hydrogen, the reaction may take the course 
represented by Figure 4b. 
 
Figure 4. Desulfurization method under Mozingo conditions (a) and in the presence of sufficient 
Raney nickel catalyst (b). 
In the desulfurization reaction under Mozingo conditions, using aliphatic and aromatic sulfides, 
disulfides, sulfoxides and sulfones with sufficient Raney nickel catalyst only the reaction (b) has been 
observed. That is, in case, the rupture of the C-S bond was accompanied by the formation of a new 
C-H bond and a combination of the organic radicals did not occur. Other methods for the replacement 
of the mercapto group by hydrogen include oxidation with nitric acid or with hydrogen peroxide in 
acidic solution [27]. In this study, the 2-unsubstituted-2-deoxo-5-deazaalloxazines derivatives were 
prepared by dethiation approach of the corresponding 2-methylthio analogs. The required 6-(o-
tolylamino) pyrimidin-4(3H)-one (7) was prepared by dethiation of 6-(N-o-tolylamino)-2-
methylthiopyrimidin-4(3H)-one (1d) by using an excess of Raney nickel and heating under reflux in 
ethanol for 0.5 h to afford 70% yield. The dethiated 5-deazaalloxazine analog, namely, 9-
methylpyrimido[4,5-b] quinolin-4-ol (8), was synthesized according to the reported procedure [8] by 
the reaction of 6-(o-tolylamino) pyrimidin-4(3H)-one (7) with Vilsmier reagent (DMF-POCl3) at 90 °C 
for 2 h to produce pale yellow needles in 80% yield, as represented in Scheme 1. 
The UV/VIS, 1H-NMR, mass spectra, IR and elemental analysis were applied to determine and 
identify the synthesized compounds. 1H-NMR spectra proved the intermediate compounds (1a–d) 
by the presence of a proton resonance as a singlet signal at 5-position at 5.04–5.51 ppm, as reported 
[8]. The cyclized 2-deoxo-2-alkylthio-5-deazaalloxazines (2b–e) exhibited a significant singlet signal 
because of the proton at C5 in the lower field at 9.01–9.18 ppm. Also, compounds (2b–d) showed a 
slight downfield shift of their 1H-NMR singlet signal of 2-SMe moieties being at 2.56–2.85 ppm owing 
to the newly cyclized conjugated tricyclic pyrimido[4,5-b] quinolin-4(3H)-one ring in comparison 
with the of uncyclized analog. Additionally, 3-NH singlet signals at 1H-NMR spectra were detected 
at 11.78–12.68 ppm for the 2-SMe cyclized derivatives (2b–d), whereas, 1H-NMR singlet signal of 3-
NH for compound 2e exhibited at an upfield shift of 9.43 ppm. This is because of the 2-ethylthio 
group has higher electron donating properties than that of the 2-methylthio group. (see 
Supplementary Materials) 
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2-(Substituted alkyl amino)-2-deoxo-5-deazaalloxazines (3a–m), 2-(heterocyclic substituted)-2-
deoxo-5-deazalloxazines (4a–g) and 2-amino-2-deoxo- 5-deazaalloxazine derivatives (5a,b) were 
characterized by vanishing the 2-methylthio group singlet signal of their precursors (2a–e). This is 
concurrent with the appearance of a singlet signal of the 2-NH at δH: 6.52–6.90 ppm for compounds 
3a–c, e–h, j–l. While the 2-NH singlet signal of the 2-(cyclohexyl amino) analogs (3d, i, m) are located 
at upfield region δH: 3.93–3.95 ppm owing to the positive inductive effect of cyclohexyl moiety. 2-
(Piperiden-1-yl)-2-deoxo-5-deazalloxazines (4a,d) are elucidated by their 6H multiplets at δH: 1.50–
1.66 ppm and 4H multiplets at δH: 3.73–3.82 ppm for the piperidinyl moiety. 2-(Morpholin-4-yl)-2-
deoxo- 5-deazalloxazines (4b,c) are elucidated by their twin 4H multiplets at δH: 3.22–3.29 and 3.70–
3.86 ppm for the morpholinyl moiety. Similarly, 2-(4-phenylpiperazin-1-yl)-pyrimido[4,5-b] 
quinoline-4-ol derivatives (4e–g) are identified by their piperazinyl two 4H multiplets at δH: 3.03–3.34 
and 3.93–3.99 ppm. 
Interestingly, the phenomenon of amide-imidol tautomerism was noticed for the 1H-NMR 
spectra for 2-deoxo-2-(4-phenylpiperazin-1-yl)-5-deazaalloaxazines (4e–g). The imidol tautomer 
predominates in 1H-NMR (DMSO-d6 at 25 °C), Figure 5. The characteristic signal of the 4-OH proton 
was detected at δH: 3.44–4.49 ppm in the 1H-NMR spectra concurrent disappearance of the singlet 
signal of the 3-NH proton. This also confirmed by the disappearance of 3-NH and C=O bands in the 
IR spectrum and displaced by the OH stretching band at 3421–3434 cm−1. 
 
Figure 5. The amide-iminol tautomerism for compounds 2-deoxo-2-(4-phenylpiperazin-1-yl)-5- 
deazaalloxazines (4e–g). 
Compounds (5a,b) are characterized by appearance of D2O exchangeable broad singlet signals 
at δH: 6.72 and 6.74 ppm belong to exocyclic 2-NH2 and broad singlet signals of 3-NH at δH: 10.81 and 
11.18 ppm, respectively. 
The 1H-NMR spectra of 2,4-dioxo-5-deazaalloxzines (6a–c), were elucidated by their two 
characteristic D2O exchangeable broad singlet signals at δH: 10.93–11.49 and 11.34–11.76 ppm which 
are corresponding to 1-NH and 3-NH, respectively. Two strong IR peaks at νcm−1 1712–1703 and 
1625–1615 cm−1 boosted their structural elucidation. 
In general, the UV spectra of 2-deoxo-2-alkylthio-5-deazalloxazines (2a–e) showed longer 
wavelength than those of compounds 3a–m, 4a–g, 5a, b, 6a–c and 8 as shown in Figure 6. This redshift 
(bathochromic shift) is attributed to the easier polarizability of the S-atom in 2-alkylthio analogs (2a–
e) [29]. The UV/VIS absorption spectra of compounds (4b–e) exhibited three absorption maxima at 
230–254, 284–287 and 362–401 nm with one absorption shoulder at 266–279 nm. While, the UV/VIS 
absorption spectra of 7-methoxy2-(substituted alkyl amino)-2-deoxo-5-deazaalloxazines (3f,g) show 
four absorption maxima at 224–230, 267–277, 327–370, 394–401 nm without any absorption shoulder. 
While the other 2-(substituted alkyl amino)-2-deoxo-5-deazaalloxazines (3a–e, h–m), 2-(heterocyclic 
substituted)-2-deoxo-5-deazaalloxazines (4a–g) and 2-amino-2-deoxo-5-deazaalloxazines (5a,b) 
show three absorption maxima together with an absorption shoulder as shown in Figure 6. 
  
Molecules 2020, 25, 2518 7 of 27 
 
Figure 6. UV–VIS spectra of 9-methyl-2-methylthio-5-deazaalloxazine (2d), 2-butylamino-9-methyl-
5-deazaalloxazine (3k), 9-methyl-2-(morpholin-4-yl)-5-deazaalloxazine (4c), 2-amino-9-methyl-5-
deazaalloxazine (5b) and 2-deoxo-5-deazaalloxazine (8). 
Based on the reported electron ionization (EI) fragmentation of N (5)-oxides of alloxazine and 
isoalloxazine derivatives [30] the principal mass spectral fragmentation routes of compounds 2,4-
dioxo-5-deazaalloxzines (6a–c) were proposed as shown in Scheme 2. This includes ions b formed by 
a retro-Diels-Alder (RDA) reaction by the ejection of an HNCO moiety from the tautomeric 
pyrimidine ring of (a) ions. The next fragmentation involved the elimination of CO or CO and H− 
species for the formation of odd-electron and even-electron ions (c) and (d), respectively. Consecutive 
ejections of HCN molecules from fragment c, with or without elimination of the H˙radical, result in 
the liberation of fragments e, f, g and h, Table 1. 
 
Scheme 2. Proposed principal of Electron Ionization Mass Spectrometry (EI-MS) fragmentation routes 
of compounds (6a–c). 
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Table 1. Elemental composition and relative abundance of the ions in the spectra of compounds 6a–c 
according to the mass spectral data. 
Ions m/z 
Elemental 
Composition 
% Relative Abundance 
6a 6b 6c 
a 
[M+] 
213 C11H7N3O2 83 ─ ─ 
227 C12H9N3O2 ─ 100 39 
b 
170 C10H6N2O 35 ─ ─ 
184 C11H8N2O ─ 34 ─ 
c 
142 C9H6N2 20 ─ ─ 
156 C10H8N2 ─ 26 ─ 
d 
141 C9H5N2 15 ─ ─ 
155 C10H7N2 ─ 23 36 
e 
115 C8H5N 80 ─ ─ 
129 C9H7N ─ 21 50 
f 
114 C8H4N 100 ─ ─ 
128 C9H6N ─ 30 100 
g 
88 C7H4 36 ─ ─ 
102 C8H6 ─ 21 32 
h 
87 C7H3 28 ─ ─ 
101 C8H5 ─ 17 44 
2.2. Antiproliferative MTT Assay 
The modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [31] 
developed by M. Tim [32] was used to determine the in vitro antiproliferative activities of the test 5-
deazaalloxazine compounds against human tumor cell lines, namely, T-cell acute lymphoblastoid 
leukemia cell line (CCRF-HSB-2) and oral epidermoid carcinoma cell line (KB), using cytosine 
arabinoside (Ara-C) as a positive control. Another two cells namely: Michigan Cancer Foundation–7 
cell line (MCF-7) and cervical cancer cell line (HeLa) were utilized relative to the % viability of 1% 
DMSO as a negative untreated control. 
As can be noticed in Table 2, 2-(cyclohexylamino)-2-deoxo-5-deazaalloxazines (3d, i and m) 
revealed reasonable antitumor activities; which were the highest among their analogs; against both 
of CCRF-HSB-2 and KB cell lines of IC50 in the range of (6.71–14.91 µM) and (6.35–17.47 µM), 
respectively, compared to the positive control Ara-C. It is noticed that 2-aminopyrimido[4,5-b] 
quinolin-4(3H)-one (5a) exhibited high selective antiproliferative activity against KB cell lines over 
CCRF-HSB-2 cell lines. Its IC50 against KB tumor cell lines was 1.46 µM, whereas, its IC50 against 
CCRF-HSB-2 cell lines was >100 µM. 
Table 2. The inhibitory activities of the synthesized 5-deazaalloxazine derivatives against CCRF-HSB-
2, KB, MCF-7 and HeLa tumor cell lines. 
Inhibitory Activity Against Tumor Cell Lines [IC50 µM)] 
Compd CCRF–HSB-2 KB Compd MCF-7 HeLa 
2b 23.66 26.73 2b 1.79 >100 
2c 35.56 30.44 2c 1.24 >100 
2d >100 >100 2d 24.72 3.40 
3a 47.21 35.47 2e >100 >100 
3d 14.91 6.93 3b 4.40 16.67 
3i 6.71 6.35 3c 8.49 0.57 
3j >100 24.9 3e 1.10 >100 
3k >100 11.62 3f 1.74 >100 
3m 9.17 17.47 3g 0.22 >100 
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4a 49.58 36.74 3h 0.17 2.00 
4c 39.14 23.79 3l >100 0.13 
4d 19.41 26.01 4b 1.25 >100 
4e 69.38 28.53 6a 2.17 >100 
4f 50.61 60.30 6b 29.45 1.39 
4g >100 23.28 6c 2.10 >100 
5a >100 1.46 8 18.22 0.33 
5b 44.64 73.81 5-FU 5.15 7.76 
Ara-c 0.14 0.26    
On the other hand, 2-(2-hydroxyethylamino)-7-methyl-pyrimido[4,5-b] quinolin-4(3H)-one (3h) 
revealed a significant antitumor activity; which was the highest among their analogs; against both of 
MCF-7 and HeLa tumor cell lines of IC50 0.17 µM and 2.00 µM as shown in Table 2, respectively. It is 
noticed that compounds (2b, 2c, 3e, 3f, 3g, 4b, 6a and 6c) revealed high selective antiproliferative 
activity against MCF-7 tumor cell lines over HeLa tumor cell lines. Their IC50 against MCF-7 tumor 
cell lines were 0.22–2.17 µM, whereas, their IC50 against HeLa tumor cell lines were >100 µM, 
respectively. Contrary, compounds (3c, 3l, 6b and 8) showed high selectivity against HeLa tumor cell 
lines over MCF-7 tumor cell lines. Their IC50 against HeLa tumor cell lines were 0.57, 0.13, 1.39 and 
0.33 µM, whereas, their IC50 against MCF-7 tumor cell lines were 8.49, >100, 29.45 and 18.22 µM, 
respectively. 
Interestingly, the IC50 of 2-hydroxyethylamino derivative (3h) was improved ten times from the 
IC50 of its starting compound 2- methylthio derivatives (2b) being of 0.17 µM and 1.79 µM, 
respectively, against MCF-7 tumor cell line. This suggested that the polar side chain at position 2 
enhances the solubility of 5- deazaalloxazine derivatives and could be essential for their antitumor 
activity. The MTT assay result of Compound 3h revealed the highest IC50 against MCF-7 breast cancer 
cell line and HeLa cervical cancer cell line (IC50 0.17 µM and 2.00 µM) in comparison to other 
compounds, which is considered as a new lead for our derivatives and motivated us for further 
investigation. Nonetheless, this result is less consistent with its binding affinity into c-Kit PTK (∆Gb: 
−11.07 kcal/mol) and room mean square deviation (RMSD) of 6.13 Å 
2.3. In Vitro Protein Kinase Assay 
Kinase profiling intends to detect the selectivity of a lead compound against a comprehensive 
panel of kinases by determining its extent of phosphorylation or dephosphorylation. The protein 
kinase profile of compound (3h) against a large group of protein kinases was evaluated using the 
33P-ATP radiometric assay method at one concentration (10 µM) in a single measurement by 
utilizing the methodology of the standardized assay, summarized in the experimental part. The PK 
profiling assay was performed by KINEXUS Bioinformatics Corporation, Canada. Two reference 
kinase inhibitors on the phosphotransferase activity were used including Imatinib (BCR-ABL 
tyrosine kinase inhibitor) and lapatinib (EGFR and HER2 dual selective tyrosine kinase inhibitor). In 
this study, the results are reported in Figure 7 and Figure 8 as the percentage change in the activation 
and inhibition in comparison with the control. The negative (−) values indicate the inhibition activity 
of target by compound, while the positive (+) values indicate the activation activity of the target. The 
percentages that more than 25% are counted to be a promising result. 
Three out of twenty kinases tested by compound (3h) exhibited reasonable inhibition scores 
ranging from −36% to −43% including FAK (−43%), CDK1/Cyclin A1 (−40%) and SCR (−36%) 
compared to the reference compound Imatinib, which showed significant inhibitory effects with FAK 
(−62%), CDK1/Cyclin A1 (−31%), SCR (−30%), respectively. Notably, seven out of twenty tested 
kinases were markedly affected by Imatinib including ABL1, BRAF, CDK1, c-Kit, FAK, FLT1 and SCR 
kinases with inhibition −88%, −44%, −31%, −47%, −62%, −42% and −30%, respectively. 
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Figure 7. Protein kinase profiling for compound (3h) at 10 µM concentration against 20 PKs compared 
to imatinib. 
Another reference compound lapatinib was used as a selective dual kinase inhibitor, which 
interrupts the HER2 and EGFR pathways. Comparing the 5-deazaalloxazine analog (3h) with 
lapatinib, the compound (3h) expressed a moderate inhibition with FAK (−43%), while lapatinib 
showed slight inhibition (−5%). Moreover, the compound (3h) revealed inhibition with BRAF (−15%) 
and FLT1 (−19%), whereas lapatinib exhibited a slightly to strongly activation with BRAF (11) and 
FLT1 (86%), as showed in Figure 8. Notably, three out of ten tested kinases were markedly affected 
by lapatinib, including ABL1, EGFR and HER2 kinases with inhibition −90%, −80%, −52%, 
respectively. However, lapatinib revealed a moderate to high activation with c-Kit and FLT1 kinases 
being of 37% to 86% that can boost the deregulation of cellular pathways in cancer patients. Generally, 
the unregulated activity of the c-Kit kinase is connected to the cancer pathogenesis in human, whereas 
c-Kit kinase activity is controlled by a tight regulation in the normal cells [33]. Profiling result of 
compound 3h revealed slight activation of the c-Kit kinase by 15%, as presented in Figure 8. 
Interestingly, the binding affinity of this compound has a slight affinity into the binding site of c-Kit 
PTK (∆Gb being of −11.07 kcal/mol) and RMSD of 6.13 Å. This docking result could elucidate the 
activation result of compound 3h against c-kit kinase. 
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Figure 8. Protein kinase profiling for compound (3h) at 10 µM concentration against 10 PKs compared 
to lapatinib. 
Overall, this profiling study revealed that the 2-hydroxyethylamino-5-deazaalloxazine analog 
(3h) has antiproliferative activity by causing multi-target kinases inhibition, including FAK (−43%), 
CDK1/Cyclin A1 (−40%) and SCR (−36%). This compound (3h) has a high solubility in aqueous 
solutions because of the polar side chain of 2-hydroxyethylamine at position 2, which could be 
responsible for its fundamental potency (36−43%), which promoted us for further lead optimization 
studies [34]. 
2.4. Annexin V PI/FITC Apoptosis Assay 
According to reported research [35,36] deazaalloxazine analogs expressed a potential capacity 
of activating the tumor suppressor protein p53 causing a subsequent cell cycle arresting and 
apoptosis. Annexin V Fluorescein Isothiocyanate/Propidium Iodide (FITC/PI) apoptosis assay was 
conducted for testing whether different concentrations of compound (3h) have apoptosis-inducing 
activity. The treated and untreated (control) were analyzed with flow cytometry (BC, FC500) after 
labeling by annexin-V FITC/PI. 
Compound (3h) was selected for apoptosis assay regarding its potential inhibitory effect on cell 
proliferation and multiple kinases, as shown in Table 2, Figures 7 and 8, respectively. Compound (3h) 
induced early and late apoptosis to MCF-7 cells in a dose-dependent pattern. The lowest 
concentration (1.0 µM) of the compound (3h) showed 56% increased late apoptosis compared to the 
control. Raising the treatment compound (3h) dose to 5 then 10 µM resulted in a potential increase in 
both early and late apoptosis. The highest treatment concentration (10 µM) produced 33% and 140% 
increase in early and late apoptosis compared to the control, respectively, as showed in Figure 9. 
Meanwhile, gathering the percentage change in early and late apoptosis between the treatment doses 
reveals that the most significant shift associated with the second concentration (5 µM). Taken together 
suggests that the highest overall apoptotic effect of compound (3h) was at a dose of (5 µM). On the 
other hand, MTT assay identified the IC50 of compound (3h) as 0.17 µM against MCF-7 tumor cell 
line. MTT assay indicates the percentage of surviving cells compared to control and cannot recognize 
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the mechanism by which the population of the treated cells was decreased [37]. Therefore, different 
compounds may generally express their antitumor effects by inhibiting different characteristic 
cellular functions and molecular pathways of cancer without directly inducing apoptosis. 
Additionally, the PK profiling study of compound (3h) demonstrates that this compound has 
antiproliferative activity by inhibition of FAK (−43%), CDK1/Cyclin A1 (−40%) and SCR (−36%). 
Herein, it can be suggested that the compound (3h) revealed antitumor activity by inhibiting the 
proliferation and causing apoptosis of the cancer cells. 
 
Figure 9. Apoptosis assay for compound 3h with different concentrations. X-axis: annexin V and Y-
axis: PI. live cells (PI−/V−): C3; early apoptotic cells (PI−/V+): C4; late apoptotic cells (PI+/V+): C2; 
necrotic cells (PI+/V−): C1. 
2.5. Structure-Activity Relationship (SAR) 
The studies of the structure-activity relationship (SAR) exhibited that the greatest antitumor 
activities were obtained with the structural features of 5-deazaalloxazin skeleton; the presence of 
ethanolamine, amino group substituent at C-2 position with unsubstituted quinoline nucleus or 
substituted by 7-Me revealed good antitumor activity as shown for compounds 3h and 5a. 
Additionally, unsubstituted quinoline scaffold or substituted by 7-OMe group, 7-Me group or 9-Me 
group with thiomethyl, ethanolamine, butylamine, propylamine, morpholine or oxo group at C-2 
position show high selective antiproliferative activity against MCF-7 tumor cell lines as shown for 
compounds 2b,c, 3e–g, 4b, 6a and 6c. Moreover, unsubstituted quinoline scaffold or substituted by a 
7-Me group or 9-Me group with cyclohexyl, propylamino, oxo group or without substitution at C-2 
position show high selective antiproliferative activity against HeLa tumor cell lines as shown for 
compounds 2c, 3i, 6b and 8. 
2.6. Molecular Docking Study 
The AutoDock binding affinities of various 5-deazaalloxizine and 5-deazaflavin analogs for their 
potential protein tyrosine inhibitory activities have been investigated [8]. Herein, the molecular 
docking study was conducted using AutoDock 4.2 [38] by docking of synthesized derivatives into 
the c-Kit receptor PTK: platelet-derived growth factor receptor (PDGFR, c-kit; PDB code: 1t46) and 
co-crystallized with the c-kit PTK inhibitor (STI571). 
The selection criteria used for molecular docking are listed as (1) full structure of the kinase 
domain of the retrieved protein from PDB structures, (2) high quality of the protein structure in this 
study the quality of chai A used is 83%, (3) minimum resolution to ensure high quantity of the 
gathered data from the used kinase (1.60 Å for PDB: 1t46), (4) Using a kinase model co-crystallized 
with inhibitor (Imatinib, Gleevec or STI-571) to be used for validation of the accuracy of the docking 
algorithm of the software (AutoDock 4.2) and (5) to ensure removal of the native co-crystallized 
ligand, water molecules and cofactor (if available) before docking. Docking accuracy will be verified 
if the bound inhibitor (STI) is docked within RMSD ≤ 2.0 Å from the natively co-crystallized pose. 
[39]. In addition, the docked compounds should reveal binding free energies (ΔGb) comparable to the 
native ligand and display a large number of hydrogen bonds with the most relevant amino acids 
(E640, T670, C673 and D810) involved in the inhibitor interaction into c-kit PTK (1t46). 
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2.6.1. AutoDock Validation 
The docking accuracy of AutoDock had been validated by docking the native cocrystallized 
ligand (STI) into its binding site of PTK (PDB: 1t46) to examine the similarity between the docked 
conformation and the original ligand [39]. The original ligand (Imatinib, Gleevec or STI-571) showed 
four hydrogen bonds with the essential amino acids of PTK: E640, T670, C673 and D810 (Figure 10). 
The docked STI ligand appeared overlapped on the original STI ligand within RMSD being of 0.17 
Å. Therefore, AutoDock validation was verified to allow further docking of the designed analogs 
[40]. These results similarly emulate the experimental results, revealing a successful docking protocol 
and confirming the accuracy of the GOLD docking program for further docking of the designed hits. 
 
Figure 10. The LIGPLOT of interactions involving the co-crystallized ligand (Imatinib, Gleevec or STI) 
revealing the most relevant amino acids (E640, T670, C673 and D810) involved in the inhibitor binding 
into c-kit kinase (PDB: 1t46), through PDBsum database. 
2.6.2. AutoDock Binding Affinities of the Synthesized Compounds into C-Kit Tyrosine Kinase 
On applying the flexible docking of the 5-deazaalloxazine derivatives into the binding site of 
PTK (PDB: 1t46), the test compounds revealed reasonable binding free energy (∆Gb) compared to the 
natively bound STI-571 ligand (Table 3). The promising poses were exhibited by compounds 2b, 2e, 
3d, 3e, 3i, 3m and 4a–d, that showed binding free energies (∆Gb) in the range of −13.71 to −12.33 
kcal/mol within RMSD range of 1.31–7.88 Å and interacting by 1–3 hydrogen bonds. 
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Table 3. The best compounds docked by flexible docking results (AutoDock 4.2), considering the 
binding free energies (ΔGb) and inhibition constants (Ki) of 5-deazalloxazine derivatives docked into 
c-kit PTK (1t46). 
Comp. 
ΔGb a 
(kcal/mol) 
Ki b 
Hydrogen Bonds  
RMSD c 
(Å) Atoms of Comp. Amino Acids 
The Most Relevant 
Amino Acids 
2b −13.04 274.65 pM N10 HN of D810 D810 1.31 
2e −12.60 577.10 pM 
3-NH 
4-C=O 
O=C of I789 
HS of C788 
- 7.28 
3a −11.87 2.00 nM 
N1 
2-NH 
Terminal OH 
HN of D810 
O=C of E640 
O=C of D810 
E640 
D810 
0.86 
3d −13.07 261.56 pM 
2-NH 
3-NH 
4-C=O 
OH of T670 
O=C of E671 
HN of C673 
T670 
E671 
C673 
6.41 
3e −12.35 889.03 pM 
3-NH 
Terminal OH 
O=C of D810 
O=C of E640 
E640 
D810 
3.07 
3h −11.07  7.68 nM 
3-NH 
Terminal OH 
OH of T670 
O=C of E640 
E640 
T670 
6.13 
3i −13.71 88.93 pM 
3-NH 
4-C=O 
2-NH 
O=C of E671 
HN of C673 
OH of T670 
T670 
C673 
E671 
6.82 
3j −11.96 1.72 nM 
2-NH 
Terminal HO 
O=C of D677 
HN of N680 
- 10.33 
3k −11.64  2.92 nM 4-C=O HN of C673 C673 7.82 
3m −12.86 373.23 pM 4-C=O HN of C673 C673 7.71 
4a −12.42 782.55 pM 4-C=O HN of C673 C673 7.44 
4b −12.41 806.85 pM 
7-O 
4-C=O 
HO of T670 
HN of C673 
T670 
C673 
7.88 
4c −12.56 624.08 pM 4-C=O  HN of C673 C673 7.56 
4d −12.33 917.97 pM 4-C=O  HN of C673 C673 7.57 
4e −11.88 1.97 nM 
3-NH 
4-C=O 
O=C of I789 
HS of C788 
- 8.91 
4g −12.22 1.10 nM 
3-NH 
4-C=O 
O=C of I789 
HS of C788 
- 8.44 
5a −11.86 2.03 nM 
4-C=O 
3-NH 
2-NH1 
2-NH1 
HN of K623 
O=C of D810 
O=C of D810 
O=C of E640 
E640 
D810 
2.46 
5b −10.45  21.92 nM 4-C=O HN of C673 C673 8.04 
STI d −16.42 915.03 fM 
HNC=O 
Ph-NH 
HN of D810 
OH of T670 
T670 
D810 
0.17 
a Binding free energy, b Inhibition constant, c Root mean square deviation, d Imatinib: the co-crystallized ligand. 
The significant PTK inhibition of compound 2b with IC50 against CCRF-HSB-2 and KB tumor 
cell lines of 23.66 and 26.73 µM, respectively and compound 3h with IC50% against MCF-7 and HeLa 
tumor cells of 0.17 and 2.0 µM, respectively were correlated with their binding affinities. Where they 
were docked into PTK (PDB: 1t46) as depicted in Figure 11 compared to the bound native ligand. 
Compound 2b revealed higher binding affinity with ΔGb: −13.04 kcal/mol and one hydrogen bond 
within RMSD of 1.31 Å. Whereas, compound 3h exhibited less binding affinity into with ∆Gb of −11.07 
kcal/mol within RMSD of 6.13Å. 3h was bound through two hydrogen bonds. This results indicated 
that compound 2b is predicted to be a significant lead compound for PTK inhibition by its 
appropriate fitting into the binding site. 
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Figure 11. The comparative binding affinities of compound 2b (colored by element, ball and stick) 
and 3h (colored by element, sticks) into the binding site of protein Tyrosine kinase (PTK) (1t46). They 
showed one and two hydrogen bonds with D810, E640 and T670 amino acids, respectively. The STI 
ligand is shown as yellow sticks. The hydrogen bonds are drawn as green dashed lines. 
On the other hand, the flexible docking of compounds 2e, 5a and 5b, exhibited comparable 
binding affinities with ∆Gb in the range of –12.60 to –10.45 kcal/mol and 1–4 hydrogen bonds, within 
RMSD in the range of 2.46–8.04 Å, as shown in Figure 12. 
 
Figure 12. Differential docking affinities of compounds 2e (bold sticks), 5a (ball and stick) and 5b (thin 
sticks) involving flexible docking into c-Kit PTK (1t46). Where compounds 2e and 5a seem docked 
exactly superimposed on the native STI ligand (yellow sticks) revealing two and four hydrogen 
bonds, whereas, 5b has deviated away with only one hydrogen bond. The c-Kit PTK is shown as a 
solid backbone ribbon and the hydrogen bonds as green dotted lines. 
The correlation between the antiproliferative activities IC50 (µg/mL) of compounds (2b, 3d, 3i, 3j, 
3m, 3k, 4a, 4c, 4d, 4e and 5a) against human CCRF-HSB-2 cell line and the AutoDock inhibition 
constants (Ki) was sensible with a correlation coefficient (R2) of 0.867 as represented in Figure 13A. 
whereas, the correlation between IC50 (µg/mL) of compounds 2b, 3a, 3d, 3i, 3j, 3m, 4a, 4c, 4d, 4e, 4g 
and 5b against human KB cell line and AutoDock binding free energies (ΔGb) showed a reasonable 
correlation coefficient (R2) of 0.834 as represented in Figure 13B. 
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Figure 13. (A) Correlation between the IC50 (µg/mL) against CCRF-HSB-2 tumor cell lines and 
AutoDock inhibition (Ki) for compounds 2b, 3d, 3i, 3j, 3m, 3k, 4a, 4c, 4d, 4e and 5a. (B) Correlation 
between the IC50 (µg/mL) against KB tumor cell lines and AutoDock binding free energy (∆Gb) for 
compounds 2b, 3a, 3d, 3i, 3j, 3m, 4a, 4c, 4d, 4e, 4g and 5b. 
To a lower extent, the correlation coefficient (R2) between Autodock inhibition (Ki) and IC50 (µM) 
against HeLa and MCF-7 tumor cell lines were 0.719 and 0.684, respectively. 
3. Experimental 
3.1. Synthesis and Structural Elucidation of 5-Deazaalloxazine Derivatives 
Using an electrothermal capillary melting point apparatus, MPs were measured as uncorrected. 
IR spectra were recorded using of infrared spectrophotometer of Perkin Elmer model 137 with KBr 
disk. A Varian Mercury VX-300 MHz spectrophotometer was used to analyze the 1H-NMR spectra 
and the chemical shift values were measured in in δ values (ppm). Tetramethylsilane (TMS) was used 
as an internal reference. The coupling constants are expressed in Hz. Both protons of NH and OH 
protons were measured as exchangeable with D2O. Gas chromatograph-mass spectrometer-single 
quadrupole (GCMC-QP)1000 EX SHIMADZU Gas Chromatography MS spectrometer was used to 
record the mass spectra. The elemental analyses were conducted by using an Automatic (Carbon; 
Hydroge; Nitrogen CHN) analyzer, Vario E1Ш, Elementary-Germany at the Microanalytical Center, 
Faculty of Science Cairo University, Egypt. All reagents in this study were used in a commercial 
quality and were not subjected for further purification. Drying of the organic solvents was performed 
by using suitable drying agents and stored over appropriate molecular sieves. Thin-layer 
chromatography (TLC) using pre-coated glass plates silica gel plates of 60F254-Merck was used for 
monitoring the progress of reactions and our fluorescent products were visualized by a UV lamp. 
3.1.1. General Procedure for the Preparation of 2-Alkylthiopyrimido[4,5-b] Quinoline-4(3H)-Ones 
{2-Deoxo-2-Alkylthio-5-Deazaalloxazines} (2a–e) 
A mixture of the appropriate 6-(N-arylamino)-2-alkylthiopyrimidin-4(3H)-one (1, 0.01 mole) and 
POCl3 (7.7 g, 0.05 mole) in (10 mL) of anhydrous DMF was heated with stirring at 90 °C for 1–2 h. 
Then, the reaction mixture was poured onto ice/water mixture and neutralized at pH 7 by aqueous 
ammonia. The separated yellow crystals were filtered off, then washed with water, dried and 
recrystallized by using DMF-H2O to produce the products as pale-yellow needles in 72–86% yields. 
2-(Methylthio)pyrimido[4,5-b]quinoline-4(3H)-one (2a): Yield (1.75 g, 72%, DMF-H2O); m.p. 292–294 °C, 
as reported [8]. 
7-Methyl-2-(methylthio)pyrimido[4,5-b]quinoline-4(3H)-one (2b): Yield (2.0 g, 78%, DMF-H2O); m.p. 244–
246 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 254 (4.03), 278sh (4.06), 285 (4.08), 366 (3.55); IR 
(νcm−1): 3421 (NH), 1672 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.51 (3H, s, 7-Me), 2.65 (3H, s, 2-SMe), 7.73 
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(1H, d, J8,9 = 6.0 Hz, 9-H), 7.90 (1H, d, J8,9 = 6.0 Hz, 8-H), 7.92 (1H, s, 6-H), 9.07 (1 H, s, 5-H), 12.61 (1H, 
br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C13H11N3OS: C, 60.68; H, 4.31; N, 16.33. 
Found: C, 60.49; H, 4.22; N, 16.69; MSEI, m/z (%): 257 (M+, 95%), 242 (6%), 226 (100%), 155 (82%). 
7-Methoxy-2-(methylthio)pyrimido[4,5-b]quinoline-4(3H)-one (2c): Yield (2.10 g, 77%, DMF-H2O); m.p. 
222–224 °C; UV (EtOH): λmaxnm (logε/dm3 mol–1cm–1): 230 (4.36), 266sh (4.39), 285 (4.40), 401 (3.51); IR 
(νcm−1): 3399 (NH), 1677 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.56 (3H, s, 2-SMe), 3.91 (3H, s, 7-OMe), 
7.57(1H, d, J8,9 = 9.0 Hz, 8-H), 7.59 (1H, s, 6-H), 7.93 (1H, d, J8,9 = 9.0 Hz, 9-H), 9.01(1H, s, 5-H), 12.68 
(1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C13H11N3O2S.0.5 DMF: C, 56.20; 
H, 4.72; N, 15.82. Found: C, 55.98; H, 4.52; N, 15.55; MSEI, m/z (%): 273 (M+, 40%), 256 (11%), 249 (36%), 
55 (100%). 
9-Methyl-2-(methylthio)pyrimido[4,5-b]quinoline-4(3H)-one (2d): Yield (2.20 g, 86%, DMF-H2O); m.p. 
200–202 °C; UV (EtOH): λmaxnm (logε/dm3 mol–1cm–1): 244 (4.35), 279sh (4.49), 287 (4.55), 367 (3.81); IR 
(νcm−1): 3412 (NH), 1681 (C=O); 1H-NMR [CDCl3-d6]: δ 2.54 (3H, s, 9-Me), 2.85 (3H, s, 2-SMe), 7.46–7.48 
(1H, m, 7-H), 7.71–7.73 (1H, m, 8-H), 7.83–7.85 (1H, m, 6-H), 9.14 (1H, s, 5-H), 11.78 (1H, br s, NH, 
D2O exchangeable); % CHN analysis: Anal. Calcd for C13H11N3OS: C, 60.68; H, 4.31; N, 16.33. Found: 
C, 60.35; H, 4.63; N, 16.01; MSEI, m/z (%): 257 (M+, 65%), 208 (100%), 154 (81%). 
2-(Ethylthio)pyrimido[4,5-b] quinoline-4(3H)-one (2e): Yield (1.90 g, 74%, DMF-H2O); m.p. 240–242 °C; 
UV (EtOH): λmaxnm (logε/dm3 mol–1cm–1): 243 (4.35), 269sh (4.40), 284 (4.53), 362 (3.79); IR (νcm−1): 3416 
(NH), 1680 (C=O); 1H-NMR [CDCl3-d6]: δ 1.52 (3H, t, J = 6.0 Hz, 2-SCH2CH3), 3.50 (2H, q, J = 6.0 Hz, 
2-SCH2CH3), 7.60 (1H, t, J6,7 = J7,8 = 7.2 Hz, 7-H), 7.91 (1H, t, J7,8 = J8,9 = 7.2 Hz, 8-H), 8.02 (1H, d, J8,9 = 7.2 
Hz, 9-H), 8.26 (1H, d, J6,7 = 7.2 Hz, 6-H), 9.18 (1 H, s, 5-H), 9.43 (1H, br s, NH, D2O exchangeable); % 
CHN analysis: Anal. Calcd for C13H11N3OS: C, 60.68; H, 4.31; N, 16.33. Found: C, 61.02; H, 4.56; N, 
16.61; MSEI, m/z (%): 257 (M+, 34%), 229 (34%), 170 (32%), 141 (94%) and 114 (100%). 
3.1.2. General Procedure for the Preparation of 2-(Substituted alkyl amino)-pyrimido[4,5-b] 
quinoline-4(3H)-ones {2-(substituted alkyl amino)-2-deoxo-5-deazaalloxazines} (3a–m) 
A 0.01 mole of 2-(methylthio)pyrimido[4,5-b]quinolin-4(3H)-one derivatives (2) was mixed and 
refluxed with stirring with 0.1 moles of the appropriate amine for 7–9 h. The clear solution of the 
yellow product was kept overnight in the refrigerator to allow precipitation of yellow crystals which 
were collected by filtration to get the first crop. The excess amine was removed from the filtrate by 
concentrating in vacuo, then the residue was treated with ether then water to get the second crop free 
from amine. The collected solids were dried and recrystallized from DMF/H2O mixture to afford pure 
products with 60–88% as yellow needles. 
2-(2-Hydroxyethylamino)pyrimido[4,5-b]quinoline-4(3H)-one (3a): Yield (2.1 g, 82%, DMF-H2O); m.p. 
273–275 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 226 (4.31), 261sh (4.25), 277 (4.34), 372 (3.49); IR 
(νcm−1): 3389 (OH), 3247 (NH), 1694 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 3.58–3.60 (2H, m, NCH2), 3.67–
3.69 (2H, m, OCH2), 5.01 (1H, br s, OH, D2O exchangeable), 6.88 (1H, br s, NH, D2O exchangeable), 
7.43 (1H, t, J6,7 = J7,8 = 9.0 Hz, 7-H), 7.78 (1H, t, J7,8 = J8,9 = 9.0 Hz, 8-H), 7.82 (1H, d, J8,9 = 9.0 Hz, 9-H), 8.06 
(1H, d, J6,7 = 9.0 Hz, 6-H), 8.92 (1H, s, 5-H), 11.10 (1H, br s, NH, D2O exchangeable); % CHN analysis: 
Anal. Calcd for C13H12N4O2: C, 60.93; H, 4.72; N, 21.86. Found: C, 61.23; H, 5.01; N, 21.54. 
2-(Butylamino)pyrimido[4,5-b]quinoline-4(3H)-one (3b): Yield (1.60 g, 60%, DMF-H2O); m.p. 153–155 °C; 
UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 243 (4.36), 263 (4.42), 278sh (4.40), 370 (3.71); IR (νcm−1): 3431, 
3256 (NH), 1691 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 0.91 (3H, br s, 2-NH(CH2)3CH3), 1.36–1.38 (2H, m, 
2-NH(CH2)2CH2-), 1.52–1.54 (2H, m, 2-NH-CH2CH2-), 3.16–3.18 (2H, m, 2-NHCH2-), 6.90 (1H, br s, 
NH, D2O exchangeable), 7.44–7.46 (1H, m, 7-H), 7.59–7.61 (1H, m, 8-H), 7.78–7.80 (1H, m, 9-H), 8.04–
8.06 (1H, m, 6-H), 8.90 (1H, s, 5-H), 10.65 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. 
Calcd for C15H16N4O.0.3 H2O: C, 65.82; H, 6.11; N, 20.47. Found: C, 65.98; H, 5.97; N, 20.26. 
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2-(Propylamino)pyrimido[4,5-b]quinoline-4(3H)-one (3c): Yield (1.90 g, 75%, DMF-H2O); m.p. 254–256 °C; 
UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 243 (4.0), 261sh (4.12), 278 (4.26), 372 (3.41); IR (νcm−1): 3448, 
3232 (NH), 1634 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 0.90–0.95 (3H, m, 2-NH(CH2)2CH3), 1.52–1.60 (2H, 
m, 2-NHCH2CH2-), 3.35–3.37 (2H, m, 2-NHCH2−), 6.68 (1H, br s, NH, D2O exchangeable), 7.43 (1H, t, 
J6,7 = J7,8 = 8.4 Hz, 7-H), 7.76 (1H, t, J7,8 = J8,9 = 8.4 Hz, 8-H), 7.82 (1H, d, J8,9 = 8.4 Hz, 9-H), 8.04 (1H, d, J6,7 
= 8.4 Hz, 6-H), 8.91 (1H, s, 5-H), 11.02 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd 
for C14H14N4O: C, 66.13; H, 5.55; N, 22.03. Found: C, 65.98; H, 5.34; N, 22.35; MSEI, m/z (%): 254 (M+, 
25%), 225 (76%), 212 (100%). 
2-(Cyclohexylamino)pyrimido[4,5-b]quinoline-4(3H)-one (3d): Yield (2 g, 68%, DMF-H2O); m.p. 229–231 
°C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 242 (4.26), 262sh (4.37), 279 (4.49), 370 (3.71); IR (νcm−1): 
3425, 3250 (NH), 1688 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 1.29–1.35 (2H, m, 4'-CH2), 1.52–1.71 (4H, m, 3' 
and 5'-CH2), 1.95–2.20 (4H, m, 2′-CH2 and 6′-CH2), 2.97–2.99 (1H, m, 1'-CH-), 3.93 (1H, br s, NH, D2O 
exchangeable), 7.40–7.42 (1H, m, 7-H), 7.80–7.82 (2H, m, 8 and 9-H), 8.04–8.06 (1H, m, 6-H), 8.91 (1H, 
s, 5-H), 10.67 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C17H18N4O: C, 69.37; 
H, 6.16; N, 19.03. Found: C, 68.01; H, 5.89; N, 18.85; MSEI, m/z (%): 294 (M+, 12%), 212 (89%), 57 (100%). 
2-(2-Hydroxyethylamino)-7-(methoxy)pyrimido[4,5-b]quinoline-4(3H)-one (3e): Yield (2.4 g, 84%, DMF-
H2O); m.p. 190–192 °C; UV (EtOH): λmaxnm (logε/dm3 mol–1cm–1): 224 (4.08), 277 (4.16), 327 (3.69), 401 
(3.23); IR (νcm−1): 3301 (OH), 3218 (NH), 1693 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 3.68–3.70 (2H, m, 
NCH2), 3.72 (3H, s, 7-OMe), 3.85–3.87 (2H, m, OCH2), 4.72 (1H, br s, OH, D2O exchangeable), 6.52 (1H, br 
s, NH, D2O exchangeable), 7.05–7.07 (1H, m, 9-H), 7.63 (1H, s, 6-H), 7.80–7.82 (1H, m, 8-H), 8.79 (1H, 
s, 5-H), 9.43 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C14H14N4O3: C, 58.73; 
H, 4.93; N, 19.57. Found: C, 58.21; H, 5.29; N, 19.25; MSEI, m/z (%): 287 (M++1, 17%), 270 (42%), 255 
(17%), 108 (100%). 
2-Butylamino-7-(methoxy)pyrimido[4,5-b]quinoline-4(3H)-one (3f): Yield (2.2 g, 74%, DMF-H2O); m.p. 
242–243 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 230 (4.37), 269 (4.41), 370 (3.67), 394 (3.66); IR 
(νcm−1): 3398, 3269 (NH), 1694 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 0.91 (3H, t, J = 7.2 Hz, 2-NH(CH2)3CH3), 
1.37–1.39 (2H, m, 2-NH(CH2)2CH2-), 1.53–1.55 (2H, m, 2-NH-CH2CH2-), 3.75–3.77 (2H, m, 2-NHCH2-
), 3.87 (3H, s, 7-OMe), 6.89 (1H, br s, NH, D2O exchangeable), 7.46–7.49 (2H, m, 6 and 9-H), 7.73–7.75 
(1H, m, 8-H), 8.83 (1H, s, 5-H), 10.98 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd 
for C16H18N4O2: C, 64.41; H, 6.08; N, 18.78. Found: C, 64.13; H, 5.82; N, 19.04; MSEI, m/z (%): 298 (M+, 
55%), 282 (8%), 270 (26%), 255 (100%), 242 (94%), 227 (59%). 
7-Methoxy-2-(propylamino)pyrimido[4,5-b]quinoline-4(3H)-one (3g): Yield (2.5 g, 88%, DMF-H2O); m.p. 
268–270 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 229 (4.36), 267 (4.45), 370 (3.60), 396 (3.69); IR 
(νcm−1): 3391, 3241 (NH), 1694 (C=O); 1H-NMR [(CD3)2SO-d6]: 0.91 (3H, t, J = 6.3 Hz, 2-NH(CH2)2CH3), 
1.58 (2H, hexet, J = 6.3 Hz, 2-NHCH2CH2-), 3.73–3.76 (2H, m, 2-NHCH2-), 3.86 (3H, s, 7-OMe), 6.52 
(1H, br s, NH, D2O exchangeable), 7.43 (1H, d, J8,9 = 9 Hz, 9-H), 7.52 (1H, s, 6-H), 7.74 (1H, d, J8,9 = 9 
Hz, 8-H), 8.81 (1H, s, 5-H), 10.93 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for 
C15H16N4O2: C, 63.37; H, 5.67; N, 19.71. Found: C, 63.14; H, 5.35; N, 19.94; MSEI, m/z (%): 284 (M+, 53%), 
269 (14%), 255 (83%), 242 (100%), 227 (48%). 
2-(2-Hydroxyethylamino)-7-(methyl)pyrimido[4,5-b]quinoline-4(3H)-one (3h): Yield (2.1 g, 78%, DMF-
H2O); m.p. 200–210 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 228 (4.32), 265 (4.44), 281sh (4.35), 
360 (3.65); IR (νcm−1): 3385 (OH), 3243 (NH), 1696 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.65 (3H, s, 7-Me), 
3.49–3.51 (2H, m, NCH2), 3.58–3.60 (2H, m, OCH2), 4.95 (1H, br s, OH, D2O exchangeable), 6.75 (1H, 
br s, NH, D2O exchangeable), 7.32–7.34 (1H, m, 9-H), 7.62 (1H, s, 6-H), 7.89–7.81 (1H, m, 8-H), 8.89 
(1H, s, 5-H), 11.12 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C14H14N4O2: C, 
62.21; H, 5.22; N, 20.73. Found: C, 62.53; H, 5.54; N, 20.52. 
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2-Cyclohexylamino-7-(methyl)pyrimido[4,5-b]quinoline-4(3H)-one (3i): Yield (2.0 g, 65%, DMF-H2O); m.p. 
220–225 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 244 (4.39), 265 (4.45), 281sh (4.37), 401 (3.73); IR 
(νcm−1): 3414, 3245 (NH), 1687 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 1.26–1.33 (2H, m, 4′-CH2), 1.83–1.90 
(4H, m, 3′ and 5′-CH2), 2.14–2.29 (4H, m,2′-CH2 and 6′-CH2), 2.63 (3H, s, 7-Me), 3.04 (1H, m, 1′-CH2), 
3.95 (1H, br s, NH, D2O exchangeable), 7.31 (1H, d, J8,9 = 8.1 Hz,, 9-H), 7.60 (1H, s, 6-H), 7.87 (1H, d, 
J8,9 = 8.1 Hz,, 8-H), 8.84 (1H, s, 5-H), 10.20 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. 
Calcd for C18H20N4O: C, 70.11; H, 6.54; N, 18.17. Found: C, 69.81; H, 6.78; N, 17.97; MSEI, m/z (%): 308 
(M+, 16%), 226 (100%). 
2-(2-Hydroxyethylamino)-9-(methyl)pyrimido[4,5-b]quinoline-4(3H)-one (3j): Yield (1.8 g, 67%, DMF-
H2O); m.p. 200–210 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 224 (4.27), 265 (4.40), 281sh (4.31), 
370 (3.72); IR (νcm−1): 3394 (OH), 3235 (NH), 1695 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.65 (3H, s, 9-Me), 
3.51–3.53 (2H, m, NCH2), 3.60–3.61 (2H, m, OCH2), 4.94 (1H, br s, OH, D2O exchangeable), 6.72 (1H, 
br s, NH, D2O exchangeable), 7.33 (1H, t, J6,7 = J7,8 = 7.5 Hz, 7-H), 7.63 (1H, d, J7,8 = 7.5 Hz, 8-H), 7.89 
(1H, d, J6,7 = 7.5 Hz, 6-H), 8.84 (1H, s, 5-H), 11.03 (1H, br s, NH, D2O exchangeable); % CHN analysis: 
Anal. Calcd for C14H14N4O2: C, 62.21; H, 5.22; N, 20.73. Found: C, 62.49; H, 5.01; N, 20.13; MSEI, m/z 
(%): 270 (M+, 32%), 252 (31%), 239 (95%), 226 (100%). 
2-Butylamino-9-(methyl)pyrimido[4,5-b]quinoline-4(3H)-one (3k): Yield (2.3 g, 82%, DMF-H2O); m.p. 
214–216 °C UV (EtOH): λmaxnm (logε/dm3 mol–1cm–1): 245 (4.54), 264 (4.70), 281sh (4.54), 360 (3.92); 
IR(νcm−1): 3412, 3237 (NH), 1698 (C=O); 1H-NMR [(CD3)2SO-d6]:δ 0.93 (3H, t, J = 6.9Hz, 2-
NH(CH2)3CH3), 1.36–1.38 (2H, m, 2-NH(CH2)2CH2-), 1.52–1.56 (2H, m, 2-NHCH2CH2-), 2.64 (3H, s, 9-
Me), 3.18–3.20 (2H, m, 2-NHCH2-), 6.65 (1H, br s, NH, D2O exchangeable), 7.31–7.33 (1H, m, 7-H), 
7.60–7.62 (1H, m, 8-H), 7.87–7.89 (1H, m, 6-H), 8.86 (1H, s, 5-H), 11.25 (1H, br s, NH, D2O 
exchangeable); % CHN analysis: Anal. Calcd for C16H18N4O: C, 68.06; H, 6.43; N, 19.84. Found: C, 
67.83; H, 6.58; N, 20.19; MSEI, m/z (%): 282 (M+, 43%), 266 (4%), 253 (19%), 239 (73%), 226 (100%). 
9-Methyl-2-(propylamino)pyrimido[4,5-b]quinoline-4(3H)-one (3l): Yield (2.1 g, 78%, DMF-H2O); m.p. 
270–272 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 244 (4.29), 265 (4.48), 281sh (4.36), 373 (3.56); IR 
(νcm−1): 3369, 3233 (NH), 1695 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 0.94–0.95 (3H, m, 2-NH(CH2)2CH3), 
1.58–1.60 (2H, m, 2-NHCH2CH2-), 2.65 (3H, s, 9-Me), 3.37–3.39 (2H, m, 2-NHCH2-), 6.63 (1H, br s, NH, 
D2O exchangeable), 7.32 (1H, t, J6,7 = J7,8 = 7.6 Hz, 7-H), 7.61 (1H, d, J7,8 = 7.6 Hz, 8-H), 7.88 (1H, d, J6,7 = 
7.6 Hz, 6-H), 8.88 (1H, s, 5-H), 10.99 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd 
for C15H16N4O: C, 67.15; H, 6.01; N, 20.88. Found: C, 67.41; H, 6.37; N, 20.69; MSEI, m/z (%): 268 (M+, 
44%), 254 (16%), 240 (79%), 226 (100%). 
2-Cyclohexylamino-9-(methyl)pyrimido[4,5-b]quinoline-4(3H)-one (3m): Yield (2.60 g, 84%, DMF-H2O); 
m.p. 178–180 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 243 (4.12), 264 (4.27), 281sh (4.10), 378 
(3.68); IR (νcm−1): 3410, 3220 (NH), 1688 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 1.26–1.40 (2H, m, 4'-CH2), 
1.44–1.72 (4H, m, 3' and 5'-CH2), 1.74–1.96 (4H, m, 2'-CH2 and 6'-CH2), 2.65 (3H, s, 9-Me), 2.89 (1H, m, 
1'-CH), 3.93 (1H, br s, NH, D2O exchangeable), 7.32 (1H, t, J6,7 = J7,8 =6 Hz, 7-H), 7.63 (1H, d, J7,8 = 6 Hz, 
8-H), 7.89 (1H, d, J6,7 = 6 Hz, 6-H), 8.87 (1H, s, 5-H), 10.23 (1H, br s, NH, D2O exchangeable); % CHN 
analysis: Anal. Calcd for C18H20N4O.0.4DMF: C, 68.30; H, 6.81; N, 18.25. Found: C, 68.59; H, 6.64; N, 
18.05. 
3.1.3. General Procedure for the Preparation of 2-(heterocyclic substituted)pyrimido[4,5-
b]quinoline-4(3H)-ones {2-(heterocyclic substituted)-2-deoxo-5-deazaalloxazines} (4a–g) 
A mixture of 2-(methyl)thiopyrimido[4,5-b]quinolin-4(3H)-one derivatives (2, 0.01 mole) and the 
appropriate amine (0.2–0.3 mole) in DMF (30 mL) was refluxed 24–30 h with stirring. The generated 
clear yellow solution was kept overnight in the refrigerator so that yellow crystals could be collected 
through filtration to get the first crop. Excessive amine was removed from the filtrate by evaporation 
under vacuo and the residue was treated with ether then water to get the second crop free from 
Molecules 2020, 25, 2518 20 of 27 
amine. The collected solids were dried and recrystallized by a DMF-H2O mixture to afford pure 
products as yellow needles in 64–75% yields. 
2-(Piperidin-1-yl)pyrimido[4,5-b]quinoline-4(3H)-one (4a): Yield (1.80 g, 64%, DMF-H2O); m.p. 228–230 
°C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 263sh (4.41), 283 (4.51), 370 (3.83), 412 (3.86); IR (νcm−1): 
3420 (NH), 1660 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 1.63–1.66 (6H, m, 3′,4′ and 5′-CH2), 3.80–3.82 (4H, 
m, 2′ and 6′-N-CH2), 7.48–7.50 (1H, m, 7-H), 7.82–7.85 (2H, m, 8 and 9-H), 8.07–8.09 (1H, m, 6-H), 8.96 
(1H, s, 5-H), 11.53 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C16H16N4O: C, 
68.55; H, 5.75; N, 19.99. Found: C, 68.39; H, 5.91; N, 19.76; MS, m/z (%): 280 (M+, 57%), 251 (66%), 225 
(39%), 55 (100%). 
7-Methoxy-2-(morpholin-4-yl)pyrimido[4,5-b]quinoline-4(3H)-one (4b): Yield (2.0 g, 64%, DMF-H2O); 
m.p. 208–210 °C; UV (EtOH): λmaxnm (logε/dm3 mol–1cm–1): 227 (4.24), 269 (4.43), 276sh (4.41), 401 
(3.66); IR (νcm−1): 3418 (NH), 1612 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 3.22–3.27 (4H, m, 3' and 5'-NCH2), 
3.76 (3H, s, 7-OMe), 3.84–3.86 (4H, m, 2' and 6'-OCH2), 7.44–7.47 (2H, m, 6 and 8-H), 7.71–7.73 (1H, 
m, 9-H), 8.80 (1H, s, 5-H), 11.40 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for 
C16H16N4O3. 0.2H2O: C, 60.83; H, 5.23; N, 17.73. Found: C, 61.03; H, 4.98; N, 17.87; MSEI, m/z (%): 312 
(M+, 71%), 255 (100%), 226 (28%). 
9-Methyl-2-(morpholin-4-yl)pyrimido[4,5-b]quinoline-4(3H)-one (4c): Yield (2.1 g, 71%, DMF-H2O); m.p. 
248–250 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 244 (4.33), 265 (4.39), 285sh (4.29), 400 (3.65); IR 
(νcm−1): 3419 (NH), 1621 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.66 (3H, s, 9-Me), 3.25–3.29 (4H, m, 3′ and 
5′-NCH2), 3.70–3.82 (4H, m, 2′ and 6′-OCH2), 7.34–7.36 (1H, m, 7-H), 7.55–7.57 (1H, m, 8-H), 7.96–7.98 
(1H, m, 6-H), 8.80 (1H, s, 5-H), 10.40 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd 
for C16H16N4O2: C, 64.85; H, 5.44; N, 18.91. Found: C, 65.12; H, 5.24; N, 19.22. 
9-Methyl-2-(piperidin-1-yl)pyrimido[4,5-b]quinoline-4(3H)-one (4d): Yield (1.90 g, 65%, DMF-H2O); m.p. 
220–222 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 246 (4.40), 266 (4.47), 288sh (4.34), 401 (3.62); IR 
(νcm−1): 3422 (NH), 1678 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 1.50–1.54 (6H, m, 3', 4' and 5'-CH2), 2.76 (3H, 
s, 9-Me), 3.73–3.75 (4H, m, 2' and 6'-NCH2), 7.31–7.33 (1H, m, 7-H), 7.62–7.64 (1H, m, 8-H), 7.88–7.90 
(1H, m, 6-H), 8.88 (1H, s, 5-H), 11.53 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd 
for C17H18N4O: C, 69.37; H, 6.16; N, 19.03. Found: C, 69.09; H, 6.35; N, 19.31; MSEI, m/z (%): 294 (M+, 
16%), 266 (8%), 253 (23%), 239 (25%), 225 (100%). 
2-(4-Phenylpiperazin-1-yl)pyrimido[4,5-b]quinoline-4-ol (4e): Yield (2.40 g, 67%, DMF-H2O); m.p. 172–
174 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 261sh (4.62), 281 (4.68), 370 (3.71), 410 (3.99); IR 
(νcm−1): 3421 (OH tautomer of C=O); 1H-NMR [(CD3)2SO-d6]: δ 3.03–3.04 (4H, m, 2' and 6'-NCH2), 3.49 
(1H, br s, OH, D2O exchangeable), 3.95–3.99 (4H, m, 3' and 5'-NCH2), 6.79 (1H, dt, J3′′,4′′ = J4′′,5′′ = 7.2 
Hz, J2′′,4′′ = J4′′,6′′ = 2.1 Hz, Ph-pH), 6.94 (2H, dd, J2′′,3′′ = J5′′,6′′ = 7.2 Hz, J2′′,4′′ = J4′′,6′′ =2.1 Hz, Ph-oH), 7.16–
7.23 (2H, m, Ph-mH), 7.45 (1H, t, J6,7 = J7,8 = 7.8 Hz, 7-H), 7.76 (1H, t, J7,8 = J8,9 = 7.8 Hz, 8-H), 7.82 (1H, 
d, J6,7 = 7.8 Hz, 6-H), 8.07 (1H, d, J8,9 = 7.8 Hz 9-H), 8.92 (1H, s, 5-H); % CHN analysis: Anal. Calcd for 
C21H19N5O: C, 70.57; H, 5.36; N, 19.59. Found: C, 70.23; H, 5.72; N, 19.32; MSEI, m/z (%): 357 (M+, 4%) 
and 132 (100%). 
7-Methyl-2-(4-phenylpiperazin-1-yl)pyrimido[4,5-b]quinoline-4-ol (4f): Yield (2.70 g, 73%, DMF-H2O); 
m.p. 279–281 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 249 (4.46), 286sh (4.15), 356 (3.50), 373 
(3.48); IR (νcm−1): 3431 (OH tautomer of C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.68 (3H, s, 7-Me), 3.27–3.34 
(4H, m, 2' and 6'-NCH2), 3.48 (1H, br s, OH, D2O exchangeable), 3.93–3.96 (4H, m, 3' and 5'-NCH2), 
6.85 (1H, t, J3′′,4′′ = J4′′,5′′ =7.5 Hz, Ph-pH), 6.97 (2H, d, J2′′,3′′ = J5′′,6′′ = 7.5 Hz, Ph-oH), 7.22-7.27 (2H, m, Ph-
mH), 7.65 (1H, d, J8,9 = 8.6 Hz, 9-H), 7.92 (1H, d, J8,9 = 8.6 Hz, 8-H), 8.16 (1H, s, 6-H), 8.93 (1H, s, 5-H); 
% CHN analysis: Anal. Calcd for C22H21N5O: C, 71.14; H, 5.70; N, 18.85. Found: C, 71.35; H, 5.42; N, 
18.47; MSEI, m/z (%): 371(M+, 0.03%, metastable ion), 162 (95%), 121 (100%). 
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9-Methyl-2-(4-phenylpiperazin-1-yl)pyrimido[4,5-b]quinoline-4-ol (4g): Yield (2.80 g, 75%, DMF-H2O); 
m.p. 281–283 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1cm−1): 266 (4.52), 287sh (4.36), 359 (3.67), 370 
(3.66); IR (νcm−1): 3434 (OH tautomer of C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.68 (3H, s, 9-Me), 3.25–3.27 
(4H, m, 2' and 6'-NCH2), 3.44 (1H, br s, OH, D2O exchangeable), 3.94–3.96 (4H, m, 3' and 5'-NCH2), 
6.89 (1H, dt, J3′′,4′′ = J4′′,5′′ = 7.8 Hz, J2′′,4′′ = J4′′,6′′ = 2.3 Hz, Ph-pH), 6.97 (2H, dd, J2′′,3′′ = J5′′,6′′ = 7.8 Hz, J2′′,4′′ 
= J4′′,6′′ = 2.3 Hz, Ph-oH), 7.17-7.24 (2H, m, Ph-mH), 7.38 (1H, t, J6,7 = J7,8 = 8.1 Hz, 7-H), 7.62 (1H, d, J7,8 = 
8.1 Hz, 8-H), 7.91 (1H, d, J6,7 = 8.1 Hz, 6-H), 8.93 (1H, s, 5-H); % CHN analysis: Anal. Calcd for 
C22H21N5O: C, 71.14; H, 5.70; N, 18.85. Found: C, 69.95; H, 5.42; N, 19.12. 
3.1.4. General Procedure for the Preparation of 2-Aminopyrimido[4,5-b]quinoline-4(3H)-ones {2-
amino-2-deoxo-5-deazaalloxazines} (5a,b) 
A mixture of 2-(methylthio)pyrimido[4,5-b]quinolin-4(3H)-one derivative (2, 4.0 mmole) and 
ammonium acetate (0.2 mole) were mixed thoroughly and fused at 160–165 °C with a vigorous 
stirring for 0.5–3.0 h. The reaction mixture was refrigerated, mixed with 15 mL of water, neutralized 
with aqueous ammonia and cooled overnight in refrigerator. The resulting brown crystals were 
collected by filtration, dried and recrystallized from DMF to give 5a,b as brown needles in 69% and 
83% yields. 
2-Aminopyrimido[4,5-b]quinolin-4(3H)-one (5a): Yield (0.70 g, 83%, DMF); m.p. >300 °C; UV (EtOH): 
λmaxnm (logε/dm3 mol−1cm−1): 260sh (4.05), 274 (4.06), 302 (3.94), 401 (3.07); IR (νcm−1): 3206, 3050 (NH), 
1681 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 6.72 (2H, br s, NH, D2O exchangeable), 7.41–7.43 (1H, m, 7-H), 
7.68–7.71 (2H, m, 6 and 8-H), 7.71–7.73 (1H, m, 9-H), 9.01 (1H, s, 5-H), 10.81 (1H, br s, NH, D2O 
exchangeable); % CHN analysis: Anal. Calcd for C11H8N4O: C, 62.26; H, 3.80; N, 26.40. Found: C, 61.94; 
H, 4.02; N, 26.21; MSEI, m/z (%): 213 (M+ + 1, 4%), 55 (100%). 
2-Amino-9-(methyl)pyrimido[4,5-b]quinolin-4(3H)-one (5b): Yield (0.62 g, 69%, DMF); m.p. >300 °C; UV 
(EtOH): λmaxnm (logε/dm3 mol−1 cm−1): 246 (4.13), 283sh (3.89), 334 (3.46), 401 (3.07); IR (νcm−1): 3275, 
3060 (NH), 1678 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.64 (3H, s, 9-Me), 6.74 (2H, br s, 2-NH2, 
exchangeable with D2O), 7.36 (1H, t, J6,7 = J7,8= 6.8 Hz, 7-H), 7.64 (1H, d, J7,8 = 6.8 Hz, 8-H), 7.90 (1H, d, 
J6,7 =6.8 Hz, 6-H), 8.87 (1H, s, 5-H), 11.18 (1H, br s, NH, D2O exchangeable); % CHN analysis: Anal. 
Calcd for C12H10N4O: C, 63.71; H, 4.46; N, 24.76. Found: C, 63.94; H, 4.72; N, 24.41; MSEI, m/z (%): 226 
(M+, 100%), 184 (10%), 157(18%). 
3.1.5. General Procedure for the Preparation of Pyrimido[4,5-b]quinoline-2,4(1H,3H)-diones{2,4-
dioxo-5-deazaalloxzines} (6a–c) 
A mixture of 2-methylthiopyrimido[4,5-b]quinolin-4(3H)-one derivatives (2a,b,d, 0.01 mole) and 
5 M hydrochloric acid (250 mL) was mixed carefully, then refluxed for 10–15 h. The precipitated 
yellow crystals were filtered off. The excess acid in the filtrate was removed under vacuo to get the 
residue. The combined first crop crystals and residue of the filtrate were collected with water then 
neutralized by aqueous ammonia to pH 7. The precipitated crystals were filtered, washed with water, 
dried and recrystallized from DMF-H2O mixture to afford yellow needles in 62–84%. 
Pyrimido[4,5-b]quinoline-2,4-dione (6a): Yield (1.60 g, 75%, DMF-H2O); m.p. >300 °C; UV (EtOH): 
λmaxnm (logε/dm3 mol−1cm−1): 219 (4.21), 235 (4.18), 252 (4.26), 307 (3.53), 355 (3.37); IR (νcm−1): 3177, 
3066 (NH), 1710, 1621 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 7.56–7.58 (1H, m, 7-H), 7.85–7.88 (2H, m, 6 
and 8-H), 8.16–8.18 (1H, m, 9-H), 9.03 (1H, s, 5-H), 11.39 (1H, br s, NH, D2O exchangeable), 11.68 (1H, 
br s, NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C11H7N3O2: C, 61.97; H, 3.31; N, 19.71. 
Found: C, 61.72; H, 3.06; N, 19.89. 
7-(Methyl)pyrimido[4,5-b]quinoline-2,4-dione (6b): Yield (1.4 g, 62%, DMF-H2O); m.p. >300 °C; UV 
(EtOH): λmaxnm (logε/dm3 mol−1cm−1): 223(4.15), 240 (4.17), 254 (4.27), 308 (3.49), 363 (3.32); IR (νcm−1): 
3205, 3019 (NH), 1703, 1615, (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.14 (3H, s, 7-Me), 7.79–7.81 (2H, m, 8, 
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9-H), 7.94 (1H, s, 6-H), 8.93 (1H, s, 5-H), 11.49 (1H, br s, 1-NH, D2O exchangeable), 11.76 ((1H, br s, 3-
NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C12H9N3O2: C, 63.43; H, 3.99; N, 18.49. 
Found: C, 63.69; H, 4.26; N, 18.72. 
9-(Methyl)pyrimido[4,5-b]quinoline-2,4-dione (6c): Yield (1.90 g, 84%, DMF-H2O); m.p. >300 °C; UV 
(EtOH): λmaxnm (logε/dm3 mol−1cm−1): 256 (4.41), 262 (4.46), 286 (4.16), 360 (3.67); IR (νcm−1): 3217, 3039 
(NH), 1712, 1625, (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.17 (3H, s, 9-Me), 7.08–7.11 (1H, m, 7-H), 7.20–
7.23 (1H, m, 8-H), 7.26–7.28 (1H, m, 6-H), 8.96 (1H, s, 5-H), 10.93 (1H, br s, 1-NH, D2O exchangeable), 
11.34 (1H, br s, 3-NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C12H9N3O2: C, 63.43; H, 
3.99; N, 18.49. Found: C, 63.39; H, 4.27; N, 18.78. 
3.1.6. General Procedure for the Preparation of 6-(o-tolylamino)pyrimidin-4(3H)-one (7) 
To a stirring solution of Raney nickel catalyst (8.0 g, 0.14 mol) in absolute ethanol (100 mL), 6-
(N-o-Tolylamino)-2-methylthiopyrimidin-4(3H)-one (1d, 0.98g, 4 mmole) was added and the mixture 
was heated under reflux for 0.5 h. The mixture was filtered while hot to remove the catalyst which 
was washed well with boiling absolute ethanol (4 × 20 mL). The combined filtrate and washings were 
evaporated to dryness. The residue was recrystallized from DMF, to afford 0.56 g of compound 7 as 
colorless needles in 70% yield; m.p. 152–154 °C; UV (EtOH): λmaxnm (logε/dm3 mol−1 cm−1): 242 (4.12), 
276 (3.93);IR (νcm−1): 3405, 3210(NH), 1637 (C=O); 1H-NMR [(CD3)2SO-d6]: δ 2.18 (3H, s, Ph-oMe), 4.83 
(1H, s, 5-H), 7.11–7.28 (4H, m, Ph-o,m,pH), 7.80 (1H, s, 2-H), 8.53 (1H, br s, 6-NH, D2O exchangeable), 
11.60 (1H, br s, 3-NH, D2O exchangeable); % CHN analysis: Anal. Calcd for C11H11N3O.0.4H2O: C, 
63.39; H, 5.71; N, 20.16. Found: C, 63.13; H, 6.08; N, 19.85. 
3.1.7. General Procedure for the Preparation of 9-(methyl)pyrimido[4,5-b]quinolin-4-ol {2-deoxo-5-
deazaalloxazine} (8) 
A mixture of 6-(o-tolylamino)pyrimidin-4(3H)-one (7, 2 g, 0.01 mole) and POCl3 (7.7 g, 0.05 mole) 
in anhydrous DMF (10 mL) was heated at 90 °C with stirring for 2 h. Followed by pouring the mixture 
onto ice and then neutralized to pH 7 by with aqueous ammonia. The product of yellow crystals was 
filtered off, washed with cold water, dried and recrystallized from mixture of DMF-H2O to give 1.70 
g. of compound 8 as pale yellow needles in 80% yield; m.p. 249–251 °C; UV (EtOH): λmaxnm (logε/dm3 
mol−1cm−1): 250 (4.18), 278sh (4.08), 336 (3.55), 365 (3.44); IR (νcm−1): 3411 (OH tautomer of C=O); 1H-
NMR [(CD3)2SO-d6]: δ 2.26 (3H, s, 9-Me), 4.01 (1H, br s, 4-OH, D2O exchangeable), 6.53 (1H, s, 2-H), 
7.54 (1H, t, J6,7 = J7,8 = 7.2 Hz, 7-H), 7.80 (1H, d, J7,8 = 7.2 Hz, 8-H), 8.09 (1H, d, J6,7 = 7.2 Hz, 6-H), 9.23 (1 
H, s, 5-H); % CHN analysis: Anal. Calcd for C12H9N3O: C, 68.24; H, 4.29; N, 19.89. Found: C, 68.66; H, 
3.96; N, 20.09; MSEI, m/z (%): 211(M+, 100%), 184 (24%), 155 (49%) and 129 (34%). 
3.2. Antiproliferative MTT Assay 
3.2.1. Antiproliferative Activities for Compounds (2b–d, 3a, d, i, j, k, m, 4a, c–g, 5a, b) Against 
CCRF-HSB and KB Tumor Cell Lines 
Four human cancer cell lines were utilized in this study to carry out cell proliferation assay, 
including CCRF-HSB-2, KB, MCF-7 and HeLa cell lines. The cell culture was conducted at 37 °C, at 
5% CO2, 95% air and 100% relative humidity. The use of the cancer cell lines was limited to 20 
passages and was checked regularly for Mycoplasma. The modified MTT assay [31] developed by M. 
Tim [32] was used to determine the in vitro antiproliferative effects of our test compounds against 
the tumor cell lines. The culture media containing the cancer cell lines were seeded in 96-well 
microplate at a density of 5 × 103 cells per each well in 100 µL of culture medium. Cells were incubated 
at 37 °C overnight to allow cell attachment. The test compounds were seeded in triplicates to the wells 
to get the final concentrations of each compound as 0.0, 0.005, 0.05, 0.5, 5, 25 and 50 µM/mL in 100 µL 
of media (0.1% DMSO for the blank control). After the incubation, 10 µL of MTT solution (10 mg/mL 
solution) was added to each well. Then incubated for 4 h at 37 °C, 100 µL of 0.02N HCl, 50% DMF 
and 20% SDS was used to dissolve the formed MTT-formazan (if any). Plates were shaken for 1 min 
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and the absorbance was examined using a multi-plate reader at λ570 nm. The IC50 (50% growth 
inhibition) was determined from the dose-response curve based on the equation: (1 − T/C) × 100, 
where C is the mean OD570 of the control group and T is that of the treated group. 
3.2.2. Antiproliferative Activities for Compounds (2b–e, 3b, c, e, f, g, h, l, 4b, 6a–c, 8) Against MCF-
7 and HeLa Tumor Cell Lines 
Cells were seeded onto sterile 96-well cell culture plates at densities of 5 × 103/well for HeLa cells 
and 2 × 104/well for MCF-7 cells. Cells were incubated at 37 °C and 5% CO2 for 24 h, after which media 
was aspirated from cells and 100 µL fresh media with/without treatments were added. Control wells 
were treated by media with DMSO concentrations equivalent to those of treatment peptides. Cells 
were further incubated at 37 °C and 5% CO2 for 72 h, followed by the addition of MTT (10 µL of a 10 
mg/mL solution) to each well. Following 2 h incubation of the plate at 37 °C and 5% CO2 and shielded 
from light with tin foil, the media was removed and the produced formazan crystals were solubilized 
by the addition of 200 µL of DMSO. The optical density of each well was measured quantitatively at 
570 nm (OD570) by EL808 HiTeck™ Spectra Thermo plate reader (HiTek Instruments, USA). The IC50 
(50% growth inhibition) was determined from the dose-response curve based on the equation: (1 − 
T/C) × 100, where C is the mean OD570 of the control group and T is that of the treated group. 
3.3. [γ-32P] ATP Radiometric Protein Kinase Assay Method 
The protein kinase profiling for compound (3h) was carried out following the protocol of 
KINEXUS Bioinformatics Corporation, Vancouver, British Columbia, Canada. This assay was 
applied for a single measurement at 10 µM concentration by [γ-32P]ATP radioisotope against a panel 
of 20 protein kinases. Both Imatinib and lapatinib were used as positive references at the same 
concentration. All experiments have been conducted in a designated radioactive environment and at 
ambient temperature for 30 min in a total volume of 25 µL in the following sequence: component 
1:5.0 µL of the active kinase (~10–50 nM final concentration), component 2:5.0 µL of the substrate 
solution. component 3: 5.0 µL of a buffer, component 4: 5.0 µL of test and reference at different 
concentrations or 10% DMSO as a blank control, component 5: 5.0 µL of [γ-32P]ATP (from 50 µM 
stock solution, 0.8 µCi). This assay was started with the addition of [γ-32P]ATP to a mixture of other 
components then incubation for 30 min. The reaction was terminated by adding 10 µL of the mixture 
onto a MultiScreen phosphocellulose P81 plate, washing 3× by 1% solution of phosphoric acid 
solution. Using a Trilux scintillation counter, the radioactivity was measured for the test samples in 
comparison to the blank control which contains all components except that the kinase substrate was 
replaced by the buffer solution. 
3.4. Annexin V PI/FITC Apoptosis Assay Using MCF7 Cells 
Cell apoptosis assay using MCF7 breast cancer cell lines (1 × 105 cells/well) was carried out by 
flow cytometry as described [41]. Briefly, MCF7 breast cancer cells were harvested by trypsinization 
and washed with ice-cold PBS (pH 7.4) twice following treatment with the test compound (3h) at final 
concentrations of 0, 1, 5, 10 µM for 72 h. Cells have been subsequently incubated with 0.5 mL of 
Annexin V-FITC/ Propidium iodide (PI) (1.0 mg/mL) solution for 30 min in dark at room temperature 
following the manufacturer’s protocol. The MCF7 cells were microscopically examined for any 
potential morphological changes before and after treatment. The floating cells were harvested in 
tubes and kept on ice, whereas, the remaining cells have been trypsinized to be detached then 
incubated for 3 min at 37 °C and pooled. At 1200 RPM at a fixed temperature of 40 °C, the cells were 
centrifuged and the supernatants have been discarded with adding 2mL fresh medium to each tube. 
Compound 3h at different concentrations was inoculated using 23 G needle and 1 × 105 MCF7 cells 
were transferred to new tubes of 12 × 75 mm tubes. The cell solutions were washed with1 mL PBS 
and again centrifuged, followed by discarding the supernatants and re-suspending the pellets in 100 
µL × 1 binding buffer (10 mM HEPES). The stained cells were injected through Becton Dickinson 
FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed for Fluorescein 
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Isothiocyanate-Propidium Iodide (FITC and PI) fluorescent signals using FL1 and FL2 signal detector, 
respectively (λex/em 488/530 nm for FITC and λex/em 535/617 nm for PI). For each sample, 12,000 
events were acquired and positive FITC and/or PI cells were quantified by quadrant analysis and 
calculated using CellQuest Software. The percentage of apoptosis was calculated according to the 
reported protocol [42] using the equation: (Sample-Control)/Control × 100 to determine the apoptosis 
and necrosis of the cell populations. 
3.5. Molecular Docking Study 
Autodock 4.2 [38], a molecular grid-based docking program, was used for flexible docking of a 
fully flexible ligand into a partially flexible protein structure. Autodock scans the binding site looking 
for the lowest energy binding energy model (s). In this study, the target kinase (PDB code, 1t46) [39] 
was retrieved solely by using ADS (Accelrys Discovery Studio) visualize v4.0 software (Accelrys Inc., 
San Diego, CA, USA). The Grid was selected to enclose the native ligand, STI-571 (Imatinib). For each 
of the docked compounds, the results of top docked runs were analyzed and assigned to the same 
cluster if their atomic coordinates have a root mean square deviation (RMSD) tolerance of 0.5 Å. Then 
these clusters were rated from the lowest binding energy to the highest. The analysis was further 
conducted for the top 10 clusters which revealed significant negative binding energies. 
3.5.1. Preparation of Target C-Kit Kinase and Ligands 
The 3D structures (PDB format) of the test compounds were constructed using Chem3D Ultra 
18.1 software [Cambridge Soft Corporation, USA (2019)]. These structures were energetically 
minimized by the use of the MOPAC package with 100 iterations and an RMS gradient of 0.10. Before 
operating with AutoDock Tool (ADT), all hydrogen atoms were added to the 3D protein structures 
and the ligands as well. Besides, Gasteigercharges (empirical atomic partial charges) were 
automatically computed by ADT on opening the ligands. To afford all different docking possibilities 
(conformers), the AutoDock program identifies all the rotatable bonds of the docked ligands. The 3D 
structure of c-Kit tyrosine kinase in complex with its co-crystallized ligand (STI-571; Imatinib) was 
retrieved as PDB format from the Protein Data Bank (PDB) web site: https://www.rcsb.org/. Then, all 
H2O molecules, bound ligands were removed deleted from the protein structure. Three amino acids, 
namely: Glu640, Thr670 and Asp810 were utilized as flexible residues during the docking protocol. 
The polar hydrogen atoms were added and the Kollman charges were automatically loaded for the 
protein 3D structure. 
3.5.2. Calculation of Autogrid Maps for the C-Kit Kinase Embracing the STI-571 Ligand 
Prior to running the docking, AutoGrid maps should be developed. These maps estimate the 
non-covalent interactions energy between the target c-kit kinase and all probe atoms in different grid 
points in the macromolecule where the ligand potentially binds. AutoGrid creates about 30 different 
types of grid maps. The created 3D grids of dimensions of 60 × 60 × 60 Å size (x, y, z) and 0.375 Å 
spacing centered at 27.696, 26.657 and 39.342 Å encompassing the binding site of the assigned kinase 
where the co-crystallized ligand; STI-571 was embedded. These grid maps were used to guide the 
docked ligands into the binding site of the c-kit kinase. Accordingly, in the Autogrid process, the size 
and position (X, y, z) of the grid box will be determined. Once these parameters have been set, 
AutoGrid will calculate the grid parameter files for each type of atom within a given area. Followed 
by running of AutoDock to automatically perform the main docking process using a Lamarckian 
Genetic Algorithm to generate all possible poses. 
As a consequence of AutoDock calculations, the output file with the top 10 conformers of the c-
kit kinase-ligand interaction will be generated with different orientations of the flexible residues and 
the ligands within the binding site. Each pose will be scored by Autodock then ranked according to 
their binding free energy of interaction. 
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4. Conclusions 
In this study, we synthesized and investigated different 5-deazaalloxazine analogs in vitro for 
their antiproliferative activities against four tumor cell lines, namely CCRF-HSB-2, KB, MCF-7 and 
HeLa. It was noticed that compounds (2b, 2c, 3e, 3f, 3g, 4b, 6a and 6c) show high selective 
antiproliferative activity against MCF-7 over HeLa tumor cell lines of IC50: 0.22–2.17 µM and >100 
µM, respectively. Whereas, other analogs showed the opposite (IC50 against HeLa cell lines: 0.33–1.39 
µM and IC50 against MCF-7 cell lines: 8.49 > 100 µM). On the other hand, Compound 5a exhibited 
high selective activity against KB over CCRF-HSB-2 tumor cell lines of IC50: 1.46 µM and >100 µM, 
respectively. 
Particularly, the most promising lead candidate from our synthesized compounds is 2-(2-
hydroxyethylamino)-7-methyl-pyrimido[4,5-b] quinolin-4(3H)-one analog (3h), which revealed 
significant antitumor activities against both of MCF-7 and HeLa tumor cell lines of IC50 0.17 µM and 
2.00 µM, respectively. Additionally, PKs target study of compound 3h illustrated that the compound 
3h induced multi- targets kinase inhibition including 43% against (FAK), −40% against (CDKI) and 
−36% against (SCR). Moreover, the Annexin-V/PI apoptotic assay elucidate that compound 3h 
showed 33% and potentially 140% increase in early and late apoptosis to MCF-7 cells respectively at 
10 µM, compared to the control. The AutoDock study of different synthesized compounds was 
conducted for lead optimization. Nonetheless, the docking result of compound 2b indicates that this 
compound is predicted to be a significant lead compound for PTK inhibition by its appropriate fitting 
into the binding site of c-Kit Kinase. This result is considerable correlated with antiproliferative 
activity of compound (2b) against MCF-7 cancer cell line with 1.79 µM. Herein, we are potentially 
suggested that the compound (3h) considerably a promising lead in comparison to the 
deazaalloxazine derivatives. 
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